We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+10.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$5.06B
AUM Growth
–
Cap. Flow
+$4.02B
Cap. Flow %
79.47%
Top 10 Hldgs %
79.91%
Holding
75
New
67
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$880M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$674M
3
GHDX
Genomic Health, Inc.
GHDX
+$448M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$420M
5
INCY icon
Incyte
INCY
+$324M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 39.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$856M 16.93%
+10,771,138
New +$880M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$608M 12.02%
+19,322,947
New +$674M
GHDX
3
DELISTED
Genomic Health, Inc.
GHDX
$433M 8.56%
+13,650,835
New +$448M
GEVA
4
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$387M 7.66%
+9,223,182
New +$420M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.47B
$362M 7.16%
+19,955,126
New +$275M
INCY icon
6
Incyte
INCY
$25.4B
$326M 6.44%
+14,810,559
New +$324M
VPHM
7
DELISTED
VIROPHARMA INC
VPHM
$244M 4.83%
+8,528,603
New +$225M
XOMA
8
DELISTED
Xoma
XOMA
$73.6M 1.46%
+1,013,729
New +$75.5M
GILD icon
9
Gilead Sciences
GILD
$165B
$63.9M 1.26%
+1,245,800
New +$64.9M
AEGR
10
DELISTED
Aegerion Pharmaceuticals
AEGR
$58.5M 1.16%
+924,343
New +$49.1M
HALO icon
11
Halozyme
HALO
$9.9B
$52.1M 1.03%
+6,553,150
New +$41.7M
RPRX
12
DELISTED
Repros Therapeutics Inc.
RPRX
$51.3M 1.01%
+2,778,654
New +$49.1M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.9B
$43.7M 0.86%
+783,311
New +$48.8M
CERS icon
14
Cerus
CERS
$569M
$37.4M 0.74%
+8,455,306
New +$40.9M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$35.2M 0.7%
+525,113
New +$23.6M
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$303M
$32M 0.63%
+3,966,179
New +$26.7M
ARIA
17
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$25.4M 0.5%
+1,450,000
New +$25.7M
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
$21.5M 0.42%
+900,000
New +$14.3M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$20.8M 0.41%
+462,847
New +$15.8M
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
$19.6M 0.39%
+796,662
New +$20M
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.7M 0.37%
+4,200,000
New +$18.8M
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$18.1M 0.36%
+1,358,857
New +$17.5M
AVNR
23
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$16.5M 0.33%
+3,578,591
New +$12.3M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$16.5M 0.33%
+1,016,433
New +$31.5M
QCOR
25
DELISTED
QUESTCOR PHARMA INC
QCOR
$14.4M 0.28%
+315,846
New +$11.2M
1
2 3

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Baker Bros. Advisors, which disclosed 75 positions worth $5.06B. Its ten largest holdings account for 80% of the portfolio.

Its largest position is PHARMACYCLICS INC: 10,771,138 shares worth $856M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets.

  • Baker Bros. Advisors's largest Q2 2013 buy was PHARMACYCLICS INC: 10,771,138 shares worth $856M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $5.06B portfolio in Q2 2013.
  • Baker Bros. Advisors disclosed 75 positions in Q2 2013, its first 13F filing on record.

Based on Baker Bros. Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.